Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage

Biofrontera Inc.

2024-Q3 EPS reported -$3.39 revenue$24,762,000

Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).
Net loss narrowed to $5.7M from $6.3M YoY; adjusted EBITDA -$4.6M vs -$3.9M.
FDA approved sNDA on Oct 4 to increase max Ameluz dosage from one to three tubes per treatment.
Phase 3 sBCC study met all endpoints: 75.9% histological clearance vs 19% placebo (p<0.0001); FDA filing expected H1 2025.
Cash and equivalents $2.9M at Sep 30, up from $1.3M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.